Trifecta-Kidney cfDNA-MMDx Study

Launched by UNIVERSITY OF ALBERTA · Jan 23, 2020

Keywords

ClinConnect Summary

The Trifecta-Kidney cfDNA-MMDx Study is a clinical trial focused on understanding kidney transplant rejection. Specifically, the study aims to see how levels of a specific type of DNA found in the blood, known as dd-cfDNA, relate to the presence of certain antibodies and the results from a diagnostic system called the Molecular Microscope® (MMDx) when patients undergo kidney biopsies. This information could help doctors better diagnose and manage kidney transplant rejections in the future.

If you are a kidney transplant recipient and your doctor has recommended a kidney biopsy, you may be eligible to participate in this study. It’s important to note that you must be able to give informed consent, and if you have received multiple organ transplants, you cannot join the study. Participants can expect to provide blood samples and undergo a biopsy, all while contributing to important research that could lead to better care for kidney transplant patients. This study is currently recruiting participants of all ages, and everyone is welcome to take part!

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All kidney transplant recipients undergoing a kidney biopsy for clinical indications, as determined by their physician or surgeon, will be eligible to enroll in the study.
• Exclusion Criteria:
• • Patients will be excluded from the study if they decline participation or are unable to give informed consent or multiple organ recipients.